<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377467</url>
  </required_header>
  <id_info>
    <org_study_id>UZH-NEP 2.1</org_study_id>
    <nct_id>NCT01377467</nct_id>
  </id_info>
  <brief_title>Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients</brief_title>
  <acronym>POSTOP</acronym>
  <official_title>A Phase 3, Investigator-initiated, Randomized, Open-label Single-center Study of the Effect of Denosumab on the Prevention of Bone Mineral Density Loss After Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rudolf Wuethrich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to examine the effect of denosumab on lumbar spine bone
      mineral density (BMD) after one year of treatment in newly transplanted renal allograft
      recipients. Secondary endpoints include BMD changes at the total hip and the femoral neck,
      changes in body height, changes in bone mineral metabolism parameters, incidence of
      fractures, and allograft function at one year. Safety measurements include the occurrence of
      rejection episodes, infectious complications, graft loss and mortality.

        -  Trial with medicinal product
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Renal allograft recipients are at high risk to suffer a substantial loss of bone mineral
      density (BMD) within the first year after kidney transplantation. This loss of BMD correlates
      with an increased risk for the development of osteoporosis or worsening of pre-existing
      osteopenia/osteoporosis, heightening the risk for the subsequent occurrence of fractures.
      Renal allograft recipients are often treated with calcium and vitamin D preparations to
      prevent BMD loss. The addition of bisphosphonates can further improve BMD. However,
      bisphosphonates are potentially nephrotoxic and promote adynamic bone disease, and are
      therefore not regularly prescribed.

      Receptor Activator of Nuclear factor- Kappa-B Ligand (RANKL) is a key molecule mediating
      development, activity, and survival of osteoclasts. Osteoporosis results in part from
      increased osteoclastic bone resorption, and therefore the inhibition of RANKL activity has
      become an obvious therapeutic strategy to prevent bone mineral density (BMD) loss and the
      development of osteoporosis.

      The novel anti-osteoporotic drug denosumab (trade name ProliaÂ®) is a fully human monoclonal
      antibody against RANKL. By inhibiting the development and the activity as well as reducing
      the survival of osteoclasts it decreases bone resorption and increases bone density.

      The hypothesis of the present study is that denosumab has a beneficial effect on the loss of
      BMD in the first year after renal transplantation. The preservation of BMD is a surrogate
      parameter, generally predicting subsequent improvements in the occurrence rate of fractures.
      The hypothesis will be tested by studying the effect of denosumab on BMD in newly
      transplanted renal allograft recipients.

      The purpose of the present trial is to study the effect of denosumab on BMD in kidney
      allograft recipients. The study participants will be treated for 1 year, receiving a total of
      2 injections of the standard 60 mg dose at baseline and at 6 months.

      Ninety sequential renal allograft recipients will be randomized 1:1 to receive two
      subcutaneous 60 mg denosumab injections within 14 days and 6 months following renal
      transplantation, or no treatment. All patients will also receive oral standard treatment with
      1000 mg calcium plus 800 IU vitamin D.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>The total lumbar spine BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in BMD at the Total Hip From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>The total hip BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in BMD at the Femoral Neck From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>The total femoral neck BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 6</measure>
    <time_frame>Baseline and month 6</time_frame>
    <description>The total lumbar spine BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in BMD at the Total Hip From Baseline to Month 6</measure>
    <time_frame>Baseline and month 6</time_frame>
    <description>The total hip BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in BMD at the Femoral Neck From Baseline to Month 6</measure>
    <time_frame>Baseline and month 6</time_frame>
    <description>The femoral neck BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-CTX at Baseline and Months 3, 6 and 12</measure>
    <time_frame>baseline, month 3, month 6, and month 12</time_frame>
    <description>Blood concentrations of beta-CTX (microgram/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P1NP at Baseline and Months 3, 6 and 12</measure>
    <time_frame>baseline, month 3, month 6, and month 12</time_frame>
    <description>Blood concentrations of P1NP were measured in microgram/L</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood Levels of Calcium (mmol/L) at Baseline and Months 0.5, 1, 2, 3, 6, 12</measure>
    <time_frame>baseline, months 0.5, 1, 2, 3, 6, 12</time_frame>
    <description>Blood levels of calcium (mmol/L) were measured at baseline and at months 0.5, 1, 2, 3, 6, and 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Levels of Phosphate (mmol/L) at Baseline and Months 0.5, 1, 2, 3, 6, 12</measure>
    <time_frame>baseline, months 0.5, 1, 2, 3, 6, 12</time_frame>
    <description>Blood levels of phosphate (mmol/L) were measured at baseline and at months 0.5, 1, 2, 3, 6, 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Levels of PTH (ng/L) at Baseline and Months 3, 6, and 12</measure>
    <time_frame>baseline and months 3, 6, and 12</time_frame>
    <description>Blood levels of PTH (ng/L) were measured at baseline and at months 3, 6, and 12</description>
  </other_outcome>
  <other_outcome>
    <measure>25-OH-vitamin D3</measure>
    <time_frame>baseline, months 3, 6, and 12</time_frame>
    <description>Blood levels of 25-OH-vitamin D3 were measured as microgramm/L</description>
  </other_outcome>
  <other_outcome>
    <measure>1,25-(OH)2 Vitamin D3</measure>
    <time_frame>baseline, months 3, 6, and 12</time_frame>
    <description>Blood levels of 1,25-(OH)2 vitamin D3 were measured as ng/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Total Volumetric Bone Mineral Densitiy (Tot.vBMD) at the Distal Tibia</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Cortical Volumetric Bone Mineral Densitiy (Ct.vBMD) at the Distal Tibia</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Trabecular Volumetric Bone Mineral Densitiy (Tb.vBMD) at the Distal Tibia</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Cortical Thickness (Ct.Th) at the Distal Tibia</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Cortical thickness was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Total Volumetric Bone Mineral Densitiy (Tot.vBMD) at the Distal Radius</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Cortical Volumetric Bone Mineral Densitiy (Ct.vBMD) at the Distal Radius</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Trabecular Volumetric Bone Mineral Densitiy (Tb.vBMD) at the Distal Radius</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Cortical Thickness (Ct.Th) at the Distal Radius</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Cortical thickness was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mm.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg denosumab s.c. at baseline and after 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab (Prolia)</intervention_name>
    <description>60 mg s.c. injection at baseline and after 6 months</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Prolia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The key inclusion criteria are:

          1. Male or female adult de novo kidney, kidney-pancreas or kidney-islet, or kidney-liver
             transplant recipients

          2. Functioning graft within 28 days after transplantation (creatinine having decreased to
             &lt;200 micromol/l without the need for dialysis)

          3. Being on standard triple immunosuppression including a calcineurin antagonist
             (cyclosporine or tacrolimus), mycophenolate (MMF or MPA) and steroids, with or without
             induction treatment with basiliximab or anti-thymocyte globulin

        Key exclusion criteria are:

          1. Age &lt;18 years

          2. Rising creatinine after initial drop &lt;200 micromol/l or creatinine &gt;200 micromol/l at
             baseline

          3. Evidence of early acute rejection, either suspected clinically and/or proven by biopsy

          4. Presence of severe osteoporosis as evidenced by a T score &lt;-4 at the hip, femoral neck
             or any of the 4 vertebrae L1 to L4

          5. Evidence of severe hyper- or hypoparathyroidism (iPTH &gt;800 ng/l or &lt;10 ng/l)

          6. Hypocalcemia (total calcium &lt;1.8 mmol/l) or hypercalcemia (total calcium &gt;2.7 mmol/l)

          7. Steroid-free de novo immunosuppression scheme
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rudolf P Wuthrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, University Hospital, Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Nephrology, University Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L, von Eckardstein A, Graf N, WÃ¼thrich RP. Effect of Twice-Yearly Denosumab on Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: A Randomized Controlled Trial. Am J Transplant. 2016 Jun;16(6):1882-91. doi: 10.1111/ajt.13692. Epub 2016 Feb 29.</citation>
    <PMID>26713403</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2011</study_first_posted>
  <results_first_submitted>January 22, 2016</results_first_submitted>
  <results_first_submitted_qc>March 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2016</results_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Rudolf Wuethrich</investigator_full_name>
    <investigator_title>Professor and Director</investigator_title>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>Denosumab</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Kidney</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from June 20, 2011, to May 2, 2014. Patients were randomized after 15.7 Â± 6.4 days after transplantation.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Denosumab</title>
          <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>No treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized patients with a functioning graft</population>
      <group_list>
        <group group_id="B1">
          <title>Denosumab</title>
          <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>No treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="16.0"/>
                    <measurement group_id="B2" value="52.9" spread="14.0"/>
                    <measurement group_id="B3" value="50.9" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of osteopenic patients</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of osteoporotic patients</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 12</title>
        <description>The total lumbar spine BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>The intention-to-treat (ITT) population was used for the primary efficacy analysis, i.e. all subjects were included that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 12</title>
          <description>The total lumbar spine BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite</description>
          <population>The intention-to-treat (ITT) population was used for the primary efficacy analysis, i.e. all subjects were included that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="3.8"/>
                    <measurement group_id="O2" value="-0.3" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We calculated that a sample size of 43 patients per group would provide a statistical power of 86% to detect a 4% difference in the percentage change of areal BMD at the total lumbar spine at 12 months, using a two-sided t-test with an Î±-level of 0.05 and assuming a mean Â± SD change of 4 Â± 6% in the denosumab group and 0 Â± 6% in the control group. To account for a dropout rate of 5%, it was planned to randomize a total of 90 patients.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.967</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.137</ci_lower_limit>
            <ci_upper_limit>6.980</ci_upper_limit>
            <estimate_desc>Percentage change in BMD was compared between the two treatment groups while controlling for the effects of baseline BMD.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in BMD at the Total Hip From Baseline to Month 12</title>
        <description>The total hip BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>The intention-to-treat (ITT) population was used for the analysis of this endpoint, i.e. all subjects were included in the analysis that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in BMD at the Total Hip From Baseline to Month 12</title>
          <description>The total hip BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite</description>
          <population>The intention-to-treat (ITT) population was used for the analysis of this endpoint, i.e. all subjects were included in the analysis that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.7"/>
                    <measurement group_id="O2" value="0.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.895</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.887</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.132</ci_lower_limit>
            <ci_upper_limit>3.659</ci_upper_limit>
            <estimate_desc>Percentage change in BMD was compared between the two treatment groups while controlling for the effects of baseline BMD.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in BMD at the Femoral Neck From Baseline to Month 12</title>
        <description>The total femoral neck BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>The intention-to-treat (ITT) was used for the analysis of this endpoint, i.e. all subjects were included in the analysis that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in BMD at the Femoral Neck From Baseline to Month 12</title>
          <description>The total femoral neck BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite</description>
          <population>The intention-to-treat (ITT) was used for the analysis of this endpoint, i.e. all subjects were included in the analysis that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="4.7"/>
                    <measurement group_id="O2" value="0.8" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.380</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.201</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.329</ci_lower_limit>
            <ci_upper_limit>3.447</ci_upper_limit>
            <estimate_desc>Percentage change in BMD was compared between the two treatment groups while controlling for the effects of baseline BMD.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 6</title>
        <description>The total lumbar spine BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite.</description>
        <time_frame>Baseline and month 6</time_frame>
        <population>The intention-to-treat was used for the analysis of this endpoint, i.e. all subjects were included in the analysis that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 6</title>
          <description>The total lumbar spine BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite.</description>
          <population>The intention-to-treat was used for the analysis of this endpoint, i.e. all subjects were included in the analysis that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="3.3"/>
                    <measurement group_id="O2" value="-1.5" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.567</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.806</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.975</ci_lower_limit>
            <ci_upper_limit>6.178</ci_upper_limit>
            <estimate_desc>Percentage change in BMD was compared between the two treatment groups while controlling for the effects of baseline BMD.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in BMD at the Total Hip From Baseline to Month 6</title>
        <description>The total hip BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite</description>
        <time_frame>Baseline and month 6</time_frame>
        <population>The intention-to-treat (ITT) population was used for the analysis of this endpoint, i.e. all subjects were included in the analysis that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in BMD at the Total Hip From Baseline to Month 6</title>
          <description>The total hip BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite</description>
          <population>The intention-to-treat (ITT) population was used for the analysis of this endpoint, i.e. all subjects were included in the analysis that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="2.4"/>
                    <measurement group_id="O2" value="-0.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.756</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.662</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.440</ci_lower_limit>
            <ci_upper_limit>3.072</ci_upper_limit>
            <estimate_desc>Percentage change in BMD was compared between the two treatment groups while controlling for the effects of baseline BMD.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in BMD at the Femoral Neck From Baseline to Month 6</title>
        <description>The femoral neck BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite</description>
        <time_frame>Baseline and month 6</time_frame>
        <population>The intention-to-treat (ITT) population was used for the analysis of this endpoint, i.e. all subjects were included in the analysis that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in BMD at the Femoral Neck From Baseline to Month 6</title>
          <description>The femoral neck BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite</description>
          <population>The intention-to-treat (ITT) population was used for the analysis of this endpoint, i.e. all subjects were included in the analysis that have been randomized to the control group or to the denosumab group. Missing values were replaced with a last-value-carried-forward approach (LVCF).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="4.0"/>
                    <measurement group_id="O2" value="-0.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.035</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.085</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.122</ci_lower_limit>
            <ci_upper_limit>4.193</ci_upper_limit>
            <estimate_desc>Percentage change in BMD was compared between the two treatment groups while controlling for the effects of baseline BMD.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beta-CTX at Baseline and Months 3, 6 and 12</title>
        <description>Blood concentrations of beta-CTX (microgram/L)</description>
        <time_frame>baseline, month 3, month 6, and month 12</time_frame>
        <population>For this endpoint, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Beta-CTX at Baseline and Months 3, 6 and 12</title>
          <description>Blood concentrations of beta-CTX (microgram/L)</description>
          <population>For this endpoint, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
          <units>microgram/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.635" lower_limit="0.508" upper_limit="0.741"/>
                    <measurement group_id="O2" value="0.772" lower_limit="0.665" upper_limit="0.878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.129" lower_limit="0.037" upper_limit="0.221"/>
                    <measurement group_id="O2" value="0.590" lower_limit="0.498" upper_limit="0.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.204" lower_limit="0.077" upper_limit="0.330"/>
                    <measurement group_id="O2" value="0.612" lower_limit="0.485" upper_limit="0.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.389" lower_limit="0.154" upper_limit="0.623"/>
                    <measurement group_id="O2" value="0.794" lower_limit="0.559" upper_limit="1.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures GLM</method>
            <param_type>between-subjects effect</param_type>
            <param_value>10.466</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Within-subjects effect: p=0.007. Time*treatment interaction: p=0.002. The a priori threshold for statistical significance is &lt;0.05.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>P1NP at Baseline and Months 3, 6 and 12</title>
        <description>Blood concentrations of P1NP were measured in microgram/L</description>
        <time_frame>baseline, month 3, month 6, and month 12</time_frame>
        <population>For this endpoints, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>P1NP at Baseline and Months 3, 6 and 12</title>
          <description>Blood concentrations of P1NP were measured in microgram/L</description>
          <population>For this endpoints, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
          <units>microgram/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.222" lower_limit="47.974" upper_limit="74.470"/>
                    <measurement group_id="O2" value="77.808" lower_limit="64.399" upper_limit="91.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.976" lower_limit="19.801" upper_limit="62.152"/>
                    <measurement group_id="O2" value="108.699" lower_limit="87.266" upper_limit="130.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.347" lower_limit="11.525" upper_limit="59.169"/>
                    <measurement group_id="O2" value="107.072" lower_limit="82.962" upper_limit="131.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.953" lower_limit="33.685" upper_limit="82.221"/>
                    <measurement group_id="O2" value="132.439" lower_limit="107.876" upper_limit="157.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures GLM</method>
            <param_type>between-subjects effect</param_type>
            <param_value>275622.016</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Within-subjects effect: p&lt;0.001. Time*treatment interaction: p=0.012. The a priori threshold for statistical significance is &lt;0.05.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Blood Levels of Calcium (mmol/L) at Baseline and Months 0.5, 1, 2, 3, 6, 12</title>
        <description>Blood levels of calcium (mmol/L) were measured at baseline and at months 0.5, 1, 2, 3, 6, and 12</description>
        <time_frame>baseline, months 0.5, 1, 2, 3, 6, 12</time_frame>
        <population>For this endpoints, an available case analysis was performed, thus all randomised patients with valid data at all time points were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Levels of Calcium (mmol/L) at Baseline and Months 0.5, 1, 2, 3, 6, 12</title>
          <description>Blood levels of calcium (mmol/L) were measured at baseline and at months 0.5, 1, 2, 3, 6, and 12</description>
          <population>For this endpoints, an available case analysis was performed, thus all randomised patients with valid data at all time points were included.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.320" lower_limit="2.245" upper_limit="2.395"/>
                    <measurement group_id="O2" value="2.317" lower_limit="2.247" upper_limit="2.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.131" lower_limit="2.049" upper_limit="2.214"/>
                    <measurement group_id="O2" value="2.405" lower_limit="2.329" upper_limit="2.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.293" lower_limit="2.231" upper_limit="2.356"/>
                    <measurement group_id="O2" value="2.444" lower_limit="2.387" upper_limit="2.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.420" lower_limit="2.355" upper_limit="2.485"/>
                    <measurement group_id="O2" value="2.480" lower_limit="2.419" upper_limit="2.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.404" lower_limit="2.327" upper_limit="2.481"/>
                    <measurement group_id="O2" value="2.461" lower_limit="2.390" upper_limit="2.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.463" lower_limit="2.404" upper_limit="2.522"/>
                    <measurement group_id="O2" value="2.453" lower_limit="2.399" upper_limit="2.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.480" lower_limit="2.421" upper_limit="2.538"/>
                    <measurement group_id="O2" value="2.509" lower_limit="2.455" upper_limit="2.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>repeated measures GLM</method>
            <param_type>between-subjects effect</param_type>
            <param_value>0.717</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Within-subjects effect: p&lt;0.001. Time*treatment interaction: p&lt;0.001. The a priori threshold for statistical significance is &lt;0.05.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Blood Levels of Phosphate (mmol/L) at Baseline and Months 0.5, 1, 2, 3, 6, 12</title>
        <description>Blood levels of phosphate (mmol/L) were measured at baseline and at months 0.5, 1, 2, 3, 6, 12</description>
        <time_frame>baseline, months 0.5, 1, 2, 3, 6, 12</time_frame>
        <population>For this endpoints, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Levels of Phosphate (mmol/L) at Baseline and Months 0.5, 1, 2, 3, 6, 12</title>
          <description>Blood levels of phosphate (mmol/L) were measured at baseline and at months 0.5, 1, 2, 3, 6, 12</description>
          <population>For this endpoints, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.582" lower_limit="0.506" upper_limit="0.657"/>
                    <measurement group_id="O2" value="0.586" lower_limit="0.514" upper_limit="0.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.525" lower_limit="0.436" upper_limit="0.613"/>
                    <measurement group_id="O2" value="0.714" lower_limit="0.631" upper_limit="0.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.605" lower_limit="0.519" upper_limit="0.691"/>
                    <measurement group_id="O2" value="0.726" lower_limit="0.645" upper_limit="0.807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.726" lower_limit="0.659" upper_limit="0.793"/>
                    <measurement group_id="O2" value="0.812" lower_limit="0.749" upper_limit="0.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.742" lower_limit="0.673" upper_limit="0.812"/>
                    <measurement group_id="O2" value="0.776" lower_limit="0.711" upper_limit="0.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.804" lower_limit="0.727" upper_limit="0.880"/>
                    <measurement group_id="O2" value="0.849" lower_limit="0.777" upper_limit="0.921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.842" lower_limit="0.737" upper_limit="0.948"/>
                    <measurement group_id="O2" value="0.902" lower_limit="0.802" upper_limit="1.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <method>repeated measures GLM</method>
            <param_type>between-subjects effect</param_type>
            <param_value>0.707</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Within-subjects effect: p&lt;0.001. Time*treatment interaction: p=0.047. The a priori threshold for statistical significance is &lt;0.05.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Blood Levels of PTH (ng/L) at Baseline and Months 3, 6, and 12</title>
        <description>Blood levels of PTH (ng/L) were measured at baseline and at months 3, 6, and 12</description>
        <time_frame>baseline and months 3, 6, and 12</time_frame>
        <population>For this endpoint, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Levels of PTH (ng/L) at Baseline and Months 3, 6, and 12</title>
          <description>Blood levels of PTH (ng/L) were measured at baseline and at months 3, 6, and 12</description>
          <population>For this endpoint, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
          <units>ng/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.110" lower_limit="115.906" upper_limit="210.314"/>
                    <measurement group_id="O2" value="147.300" lower_limit="100.096" upper_limit="194.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.573" lower_limit="130.141" upper_limit="217.004"/>
                    <measurement group_id="O2" value="111.563" lower_limit="68.131" upper_limit="154.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.043" lower_limit="117.092" upper_limit="196.993"/>
                    <measurement group_id="O2" value="99.420" lower_limit="59.469" upper_limit="139.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.650" lower_limit="85.078" upper_limit="128.222"/>
                    <measurement group_id="O2" value="100.705" lower_limit="79.133" upper_limit="122.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.114</p_value>
            <method>repeated measures GLM</method>
            <param_type>between-subjects effect</param_type>
            <param_value>99952.126</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Within-subjects effect: p&lt;0.001. Time*treatment interaction: p=0.047. The a priori threshold for statistical significance is &lt;0.05.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>25-OH-vitamin D3</title>
        <description>Blood levels of 25-OH-vitamin D3 were measured as microgramm/L</description>
        <time_frame>baseline, months 3, 6, and 12</time_frame>
        <population>For this endpoint, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>25-OH-vitamin D3</title>
          <description>Blood levels of 25-OH-vitamin D3 were measured as microgramm/L</description>
          <population>For this endpoint, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
          <units>microgramm/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.378" lower_limit="14.690" upper_limit="20.067"/>
                    <measurement group_id="O2" value="18.058" lower_limit="15.336" upper_limit="20.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.632" lower_limit="19.604" upper_limit="23.659"/>
                    <measurement group_id="O2" value="22.903" lower_limit="20.850" upper_limit="24.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.395" lower_limit="21.418" upper_limit="27.373"/>
                    <measurement group_id="O2" value="26.728" lower_limit="23.713" upper_limit="29.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.546" lower_limit="25.890" upper_limit="31.202"/>
                    <measurement group_id="O2" value="28.358" lower_limit="25.669" upper_limit="31.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.578</p_value>
            <method>repeated measures GLM</method>
            <param_type>between-subjects effect</param_type>
            <param_value>84.830</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Within-subjects effect: p&lt;0.001. Time*treatment interaction: p=0.593. The a priori threshold for statistical significance is &lt;0.05.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>1,25-(OH)2 Vitamin D3</title>
        <description>Blood levels of 1,25-(OH)2 vitamin D3 were measured as ng/L</description>
        <time_frame>baseline, months 3, 6, and 12</time_frame>
        <population>For this endpoint, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>1,25-(OH)2 Vitamin D3</title>
          <description>Blood levels of 1,25-(OH)2 vitamin D3 were measured as ng/L</description>
          <population>For this endpoint, an available case analysis was performed, i.e., all randomised patients with valid data at all time points were included.</population>
          <units>ng/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.556" lower_limit="21.977" upper_limit="37.134"/>
                    <measurement group_id="O2" value="34.171" lower_limit="26.373" upper_limit="41.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.533" lower_limit="52.678" upper_limit="68.389"/>
                    <measurement group_id="O2" value="55.276" lower_limit="47.193" upper_limit="63.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.175" lower_limit="46.883" upper_limit="61.467"/>
                    <measurement group_id="O2" value="58.074" lower_limit="50.570" upper_limit="65.577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.208" lower_limit="39.902" upper_limit="54.515"/>
                    <measurement group_id="O2" value="51.494" lower_limit="43.976" upper_limit="59.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.607</p_value>
            <method>repeated measures GLM</method>
            <param_type>between-subjects effect</param_type>
            <param_value>248.686</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Within-subjects effect: p&lt;0.001. Time*treatment interaction: p=0.296. The a priori threshold for statistical significance is &lt;0.05.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Total Volumetric Bone Mineral Densitiy (Tot.vBMD) at the Distal Tibia</title>
        <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Volumetric Bone Mineral Densitiy (Tot.vBMD) at the Distal Tibia</title>
          <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.</description>
          <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.7" upper_limit="3.2"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-3.3" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>z value</param_type>
            <param_value>-2.342</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Cortical Volumetric Bone Mineral Densitiy (Ct.vBMD) at the Distal Tibia</title>
        <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Cortical Volumetric Bone Mineral Densitiy (Ct.vBMD) at the Distal Tibia</title>
          <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.</description>
          <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.5" upper_limit="1.4"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-2.0" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>z value</param_type>
            <param_value>-2.049</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Trabecular Volumetric Bone Mineral Densitiy (Tb.vBMD) at the Distal Tibia</title>
        <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Trabecular Volumetric Bone Mineral Densitiy (Tb.vBMD) at the Distal Tibia</title>
          <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.</description>
          <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.3" upper_limit="4.2"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-2.5" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>z value</param_type>
            <param_value>-0.937</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Cortical Thickness (Ct.Th) at the Distal Tibia</title>
        <description>Cortical thickness was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mm.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Cortical Thickness (Ct.Th) at the Distal Tibia</title>
          <description>Cortical thickness was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mm.</description>
          <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.4" upper_limit="8.0"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-5.9" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>z value</param_type>
            <param_value>-2.752</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Total Volumetric Bone Mineral Densitiy (Tot.vBMD) at the Distal Radius</title>
        <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Volumetric Bone Mineral Densitiy (Tot.vBMD) at the Distal Radius</title>
          <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.</description>
          <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-1.9" upper_limit="2.2"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-5.2" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>z value</param_type>
            <param_value>-2.166</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Cortical Volumetric Bone Mineral Densitiy (Ct.vBMD) at the Distal Radius</title>
        <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Cortical Volumetric Bone Mineral Densitiy (Ct.vBMD) at the Distal Radius</title>
          <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.</description>
          <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-1.8" upper_limit="1.3"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-2.7" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.212</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>z value</param_type>
            <param_value>-1.288</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Trabecular Volumetric Bone Mineral Densitiy (Tb.vBMD) at the Distal Radius</title>
        <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Trabecular Volumetric Bone Mineral Densitiy (Tb.vBMD) at the Distal Radius</title>
          <description>Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.</description>
          <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.1" upper_limit="4.1"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-9.4" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>z value</param_type>
            <param_value>-1.640</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Cortical Thickness (Ct.Th) at the Distal Radius</title>
        <description>Cortical thickness was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mm.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Cortical Thickness (Ct.Th) at the Distal Radius</title>
          <description>Cortical thickness was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mm.</description>
          <population>Subgroup of patients (n=24) who participated in the HR-pQCT (Xtreme CT) subprotocol.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="-6.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-3.6" lower_limit="-7.7" upper_limit="-1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>z value</param_type>
            <param_value>-1.991</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Denosumab</title>
          <description>60 mg denosumab s.c. at baseline and after 6 months
Denosumab (Prolia): 60 mg s.c. injection at baseline and after 6 months</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>No treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes (post-transplant)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Choledocholithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute rejection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Transplant pyelonephritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>CMV viremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Flu-like disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Retinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Infection without focus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck/back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Functional decline of transplant function</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Transplant ureter stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Transplant artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bilateral nephrectomy of polycystic kidneys</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Ureteral leakage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urethral stricture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterus myomatosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical intervention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Transplant reflux testing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Selective ureteral sampling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Peripheral arterial vascular disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Transient, asymptomatic hypocalcemia defined as total serum calcium &lt;1.9 mmol/L</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Fecal blood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <description>Cystitis (bladder infection)</description>
                <counts group_id="E1" events="39" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E2" events="19" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Aphtous stomatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neck/back pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exanthema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Rudolf P. WÃ¼thrich</name_or_title>
      <organization>University Hospital ZÃ¼rich</organization>
      <phone>+41 44 255 33 84</phone>
      <email>rudolf.wuethrich@usz.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

